Lexaria Announces R&D on Nicotine Kelowna, BC /

Lexaria Announces R&D on Nicotine

Kelowna, BC / May 4, 2017 / Lexaria Bioscience Corp

(OTCQB:LXRP) (CSE:LXX) (the Company , Lexaria ) is announcing new plans to

commence nicotine absorption research beginning in the summer of 2017, within

its previously announced R&D budget that is fully funded.

Lexaria is developing leading technology for the more effective

gastro-intestinal delivery of cannabinoids, vitamins, pain relievers, and other

active molecules. Many active molecules are currently delivered in formats that

are not conducive to human health and there is no better example than cigarette

smoking that delivers nicotine.

Lexaria believes there are large and untapped markets available

including for more efficient and healthy delivery of nicotine through edible

products. In fact, nicotine administration in controlled studies has been found

to be a potentially healthful molecule including in some studies shown to

potentially be related to a decrease in incidence of Parkinson s disease.

(University of Washington, Journal of

Despite the fact that cigarette smoking is the leading cause of

preventable death in the world (Euromonitor International and the World

Health Organization) the global cigarette industry was worth $699 billion in

2015 with over 5.5 trillion cigarettes sold to over 1 billion customers. Current

trends show that tobacco use will cause more than 8 million annual deaths by

2030. (Centers for Disease Control and Prevention)

In 2017 Lexaria will perform its first ever nicotine absorption

studies utilizing human intestinal tissue in an in vitro environment, to

determine whether Lexaria s technology assists in greater absorption of nicotine

across the intestinal wall.

Positive 2017 results from Lexaria s in vitro nicotine

testing would support the concept that an edible product containing nicotine

could form an alternative to cigarettes as a nicotine delivery system. If

successful, in vivo follow-up testing would be required to determine

whether the Lexaria technology also aids in intestinal tolerance.

Lexaria currently has a total of 18 patents pending including

for applying its technology to nicotine delivery - and patent applications filed

in more than 40 countries around the world.

Lexaria Bioscience Corp. is a food biosciences company with a

proprietary technology for improved delivery of bioactive compounds. The

Company s lipophilic enhancement technology has been shown to enhance the

bioavailability of orally ingested cannabinoids, while also masking taste. This

technology promotes healthy ingestion methods, lower overall dosing and higher

effectiveness in active molecule delivery. The Company s technology is

patent-protected for cannabidiol (CBD) and all other non-psychoactive

cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other

psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs),

nicotine and other molecules.

FOR FURTHER INFORMATION PLEASE CONTACT:

FORWARD-LOOKING STATEMENTS

This release includes

forward-looking statements. Statements which are not historical facts are

forward-looking statements. The Company makes forward-looking public statements

concerning its expected future financial position, results of operations, cash

flows, financing plans, business strategy, products and services, competitive

positions, growth opportunities, plans and objectives of management for future

operations, including statements that include words such as "anticipate," "if,"

"believe," "plan," "estimate," "expect," "intend," "may," "could," "should,"

"will," and other similar expressions are forward-looking statements. Such

forward-looking statements are estimates reflecting the Company's best judgment

based upon current information and involve a number of risks and uncertainties,

and there can be no assurance that other factors will not affect the accuracy of

such forward-looking statements. Factors which could cause actual results to

differ materially from those estimated by the Company include, but are not

limited to, government regulation, managing and maintaining growth, the effect

of adverse publicity, litigation, competition, the patent application and

approval process and other factors which may be identified from time to time in

the Company's public announcements and filings. There is no assurance that

existing capital is sufficient for the Company's needs or that it will be able

to raise additional capital. There is no assurance that Lexaria will

successfully complete any other contemplated or existing technology license

agreements, nor that Lexaria s technology will deliver any improvement in taste

or bioavailability with any reliability nor across any product category. There

is no assurance that any planned corporate activity, business venture, or

initiative will be pursued, or if pursued, will be successful. There is no

assurance that any hemp oil or cannabinoid-based product will promote, assist,

or maintain any beneficial human health conditions whatsoever, nor that any

patent application in the USA or any other nation or under any treaty will

result in the award of an actual patent; nor that an award of any actual patent

will protect against challenges from unknown third parties. There is no

assurance that any of Lexaria s postulated uses, benefits, or advantages for the

patent-pending technology will in fact be realized in any manner or in any part.

No statement herein has been evaluated by the Food and Drug Administration

(FDA)or by Health Canada. Lexaria products are not intended to diagnose, treat,

cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility

for the adequacy or accuracy of this release.